Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 4Completed 4Active not recruiting 2Withdrawn 1Terminated 1Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 4Gastrointestinal 4Lymphoid 3Genitourinary 3Tumor-Agnostic 2Myeloid 2CNS 2Breast 2Thoracic 1Sarcoma 1Gynecologic 1Classical hematology 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Anemia, Refractory, with Excess of Blasts 1

Interventions

TAK-243 1Specimen Handling 1Passive Cutaneous Anaphylaxis 1Morphine 1Methadone 1Hydromorphone 1Blood Transfusion 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Biopsy × Classical hematology × Clear all
NCT03816319 2026-05-18

TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts

National Cancer Institute (NCI)

Phase 1 Suspended
42 enrolled
Classical hematologyMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡